Business
Advicenne secures its cash runway to Q2 2027 through a bond financing of a nominal amount of up to EUR3.8 million
Advicenne secures its cash runway to Q2 2027 through a bond financing of a nominal amount of up to EUR3.8
About this update from Advicenne Sa
Paris, France - Advicenne S.A. (' Advicenne ' or the 'Company') (Euronext Growth Paris - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and marketing of innovative treatments for people suffering from rare kidney diseases, announced that it has secured a two-tranche financing of a nominal amount of up to EUR3.8 million , through the issuance of bonds subscribed by Cemag Invest and Didier Laurens , Chairman of the Board and CEO of Advicenne , and new investors, Europe Offering and a fund managed by L1 Capital . This financing extends Advicenne's financial outlook to the second quarter of 2027, within the framework of the ongoing safeguard proceedings. It provides the Company with the flexibility required to finalize the U.S . registration of ADV7103, its proprietary asset, in distal Renal Tubular Acidosis (dRTA) and to execute its financial restructuring through the ongoing safeguard proceedings. Didier Laurens , Chairman and CEO of Advicenne , stated: 'I would like to sincerely thank the investors, and especially Cemag Invest, for their valuable support and renewed confidence. This financing is perfectly tailored to meet the Company's cash requirements. Its structure will enable us to complete our safeguard plan with all stakeholders in an efficient manner, while preserving our flexibility to continue Advicenne's strategic development, particularly obtaining marketing authorization for ADV7103 in the United States . I have personally committed to participating in this financing, as a mark of my confidence in the success of both our development projects and financial restructuring.' This financing consists of: a first bond issue in the form of straight bonds with a nominal value of up to EUR1.6 million . These bonds will be subscribed by Cemag Invest, a long-standing shareholder of Advicenne , Didier Laurens , Chairman and CEO of Advicenne , and Europe Offering. The Company will additionally issue them stock subscription warrants and a second bond issue in the form of convertible bonds with a nominal value of up to EUR2.2 million . These bonds will be subscribed by a fund managed by L1 Capital . Both financing benefit pari passu from the 'post-money' privilege provided for by articles L. 622-17 III 2-degree and L. 631-14 of the French Commercial Code, granted by the supervising judge (Juge commissaire) of the Paris Commercial Court on June 15, 2026 . As part of this financing, the Company today completed an initial issuance of (i) straight bonds with a nominal value of EUR400,000 and stock warrants, and, in addition, (ii) convertible bonds with a nominal value of EUR1.1 million . The resulting total net cash infusion of EUR1.4 million enables the Company to approach the upcoming deadlines of the ongoing safeguard proceedings with confidence, while continuing its strategic plan. ABOUT ADVICENNE Advicenne (Euronext Growth Paris ALDVI - FR0013296746) is a specialty pharmaceutical company founded in 2007, specializing in the development of innovative treatments in Nephrology. Its lead product Sibnayal (ADV7103) has received its Marketing Approval for distal renal tubular acidosis in EU, GB, KSA and UAE, and has been filed for a US NDA. ADV7103 is currently in late-stage development in cystinuria in Europe and in dRTA and cystinuria in the US and in Canada. Headquartered in Paris, Advicenne, listed on the Euronext Paris stock exchange since 2017, has now been listed on Euronext Growth Paris since its transfer on March 30, 2022. Contact: Didier Laurens Tel: +33 (0) 1 87 44 40 17 Email: [email protected] Bruno Arabian Tel: +33 (0)6 87 88 47 26 Email: [email protected] (C) 2026 Electronic News Publishing, source ENP Newswire